BACKGROUND: Characteristics of glucose metabolism disorders (GMDs) in different cancers and the contributory role of GMDs in developing cancers are still not so clear. METHODS: Two thousand four hundred and five patients with malignancy who had been hospitalized in the First Affiliated Hospital of Jinan University were pooled as case group. Two thousand and sixteen non-cancer people who finished health examinations in the Affiliated Yangcheng Hospital of Guangzhou Medical College were enrolled as control group. We compared glucose metabolism among patients with different kinds of malignancy. Based on logistic regression models, we analyzed factors that affect the development of carcinoma. RESULTS: (1) Among 2,408 malignancy patients, the total prevalence of diabetes mellitus (DM) and impaired fasting glucose (IFG) reached 28.0%. Pancreatic cancer, lymphoma, liver cancer, leukemia, and colorectal cancer showed most striking hyperglycemia. (2) Leukemia and esophageal cancer accounting for 12.5% and 12.1%, respectively, were the most likely to suffer from hypoglycemia. (3) Older cancer patients seem to be more vulnerable to hyperglycemia, while the younger tend to be more likely to develop hypoglycemia. (4) High level of fasting plasma glucose (FPG) was associated with lung cancer, breast cancer, leukemia, lymphoma, thyroid cancer, bladder cancer, and pancreatic cancer. Patients with DM increased risks for developing colorectal cancer, liver cancer, esophageal cancer, thyroid cancer, cervical cancer, and pancreatic cancer. CONCLUSIONS: GMDs are frequent events in malignancy patients. Hyperglycemia and hypoglycemia are found in the same kinds or different kinds of cancers, and the incidence of hyperglycemia is higher than that of hypoglycemia. Characteristics of GMDs were dissimilar in different cancers and different ages. Hyperglycemia was a risk factor for many cancers.
BACKGROUND: Characteristics of glucose metabolism disorders (GMDs) in different cancers and the contributory role of GMDs in developing cancers are still not so clear. METHODS: Two thousand four hundred and five patients with malignancy who had been hospitalized in the First Affiliated Hospital of Jinan University were pooled as case group. Two thousand and sixteen non-cancerpeople who finished health examinations in the Affiliated Yangcheng Hospital of Guangzhou Medical College were enrolled as control group. We compared glucose metabolism among patients with different kinds of malignancy. Based on logistic regression models, we analyzed factors that affect the development of carcinoma. RESULTS: (1) Among 2,408 malignancypatients, the total prevalence of diabetes mellitus (DM) and impaired fasting glucose (IFG) reached 28.0%. Pancreatic cancer, lymphoma, liver cancer, leukemia, and colorectal cancer showed most striking hyperglycemia. (2) Leukemia and esophageal cancer accounting for 12.5% and 12.1%, respectively, were the most likely to suffer from hypoglycemia. (3) Older cancerpatients seem to be more vulnerable to hyperglycemia, while the younger tend to be more likely to develop hypoglycemia. (4) High level of fasting plasma glucose (FPG) was associated with lung cancer, breast cancer, leukemia, lymphoma, thyroid cancer, bladder cancer, and pancreatic cancer. Patients with DM increased risks for developing colorectal cancer, liver cancer, esophageal cancer, thyroid cancer, cervical cancer, and pancreatic cancer. CONCLUSIONS: GMDs are frequent events in malignancypatients. Hyperglycemia and hypoglycemia are found in the same kinds or different kinds of cancers, and the incidence of hyperglycemia is higher than that of hypoglycemia. Characteristics of GMDs were dissimilar in different cancers and different ages. Hyperglycemia was a risk factor for many cancers.
Authors: Daniel N Nan; Marta Fernández-Ayala; Maria E Vega Villegas; Almudena Garcia-Castaño; Fernando Rivera; Marta Lopez-Brea; Jesús González-Macías Journal: Acta Oncol Date: 2003 Impact factor: 4.089
Authors: Oliver Stoeltzing; Wenbiao Liu; Niels Reinmuth; Fan Fan; Alexander A Parikh; Corazon D Bucana; Douglas B Evans; Gregg L Semenza; Lee M Ellis Journal: Am J Pathol Date: 2003-09 Impact factor: 4.307
Authors: Suresh T Chari; Cynthia L Leibson; Kari G Rabe; Lawrence J Timmons; Jeanine Ransom; Mariza de Andrade; Gloria M Petersen Journal: Gastroenterology Date: 2007-10-26 Impact factor: 22.682
Authors: E W Richards; C L Long; K M Nelson; J A Pinkston; R M Navari; J W Geiger; R E Gandy; W S Blakemore Journal: Nutrition Date: 1992 Jul-Aug Impact factor: 4.008
Authors: Rachel Huxley; A Ansary-Mohaddam; R Huxley; F Barzi; T H Lam; K Jamrozik; T Ohkubo; X Fang; H J Sun; M Woodward; D F Gu; A Rodgers; Y Imai; W H Pan; I Suh; H J Sun; H Ueshima Journal: Asian Pac J Cancer Prev Date: 2007 Apr-Jun
Authors: Marc J Gunter; Donald R Hoover; Herbert Yu; Sylvia Wassertheil-Smoller; Joann E Manson; Jixin Li; Tiffany G Harris; Thomas E Rohan; Xiaonan Xue; Gloria Y F Ho; Mark H Einstein; Robert C Kaplan; Robert D Burk; Judith Wylie-Rosett; Michael N Pollak; Garnet Anderson; Barbara V Howard; Howard D Strickler Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-04 Impact factor: 4.254
Authors: Briseis Aschebrook-Kilfoy; Mona M Sabra; Alina Brenner; Steven C Moore; Elaine Ron; Arthur Schatzkin; Albert Hollenbeck; Mary H Ward Journal: Thyroid Date: 2011-07-18 Impact factor: 6.568